PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

Automated summary

The molecular classification of diffuse large B cell lymphoma has enabled precision medicine targeting specific oncogenic pathways. In this study, Wilson et al. conducted a comprehensive genomic analysis to identify molecular signatures associated with differential responses to ibrutinib plus R-CHOP combination therapy.